Home » Stocks » DRMA » Company

Dermata Therapeutics, Inc. (DRMA)

Dermata Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: $7.00 - $9.00
Current IPO price range
Dermata Therapeutics, Inc.
Country United States
Founded 2014
IPO Date Pending
Industry Pharmaceutical Preparations
Sector Biotechnology
Employees 7
CEO Gerald T. Proehl

Contact Details

Address:3525 Del Mar Heights Rd., #322
San Diego, CA 92130
United States
Phone (858) 800-2543
Websitedermatarx.com

Stock Information

Ticker Symbol DRMA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 1853816
Employer ID 86-3218736

Company Description

Dermata Therapeutics is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions.

Our Spongilla technology platform is based on the use of a naturally growing freshwater sponge, Spongilla lacustris, or Spongilla. Traditionally, locals would harvest the sponge to be used as a folk medicine to treat various inflammatory ailments, but research has been conducted to evaluate the use of Spongilla for the possible treatment of various skin diseases and aesthetic conditions.

Our lead product candidate, DMT310, a once-weekly topical product, is the first product candidate being developed from our Spongilla technology platform.

Based on DMT310’s multiple mechanisms of action, it is currently under clinical development for the treatment of acne vulgaris (or acne), psoriasis vulgaris (or psoriasis), and papulopustular rosacea.

We recently received results from our Phase 2b clinical trial of DMT310 for the treatment of moderate-to-severe acne. This trial produced statistically significant results for all efficacy endpoints.

The clinical endpoints used in the Phase 2b trial are identical to those endpoints we intend to use in our two Phase 3 acne clinical trials, which trials we believe will form the basis of our new drug application for DMT310.

Key Executives

NamePosition
Gerald T. ProehlPresident, Chief Executive Officer and Chairman
Thomas H. InsleyChief Financial Officer
Christopher J. Nardo, M.P.H., Ph.D.Senior Vice President, Development
Maria Bedoya Toro Munera, Ph.D., M.B.A.Senior Vice President, Regulatory Affairs & Quality Assurance
David HaleLead Director
Wendell Wierenga, Ph.D.Director
Kathleen ScottDirector
Stephen J. Mento, Ph.D.Director